BridgeMD
New treatment option for Neuroblastoma
Official title 68Ga-DOTATATE Neuroblastoma Imaging Pilot
ClinicalTrials.gov ID: NCT04559217
What this study is testing
What is Radiopharmaceutical 68Ga-DOTATATE?
Radiopharmaceutical 68Ga-DOTATATE is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for neuroblastoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Neuroblastoma is the most frequent extracranial childhood tumor, with an annual incidence of approximately 10.2 per million children. Staging of the disease can be done by different imaging strategies (CT, MRI, scintigraphy and PET/CT).
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages up to 21
You may be able to join if
- Newly suspected or biopsy-proven neuroblastoma or recurrence of neuroblastoma
- Planned 123I-MIBG imaging
- Able and willing to provide signed informed consent in French or English (for the adult candidates or the parent/legal tutor of the pediatric...
- Aged between 1 day and 21 years old (inclusively).
You likely can't join if
- History of another cancer in the past 5 years other than non-melanomatous skin cancer.
- Currently under a assigned by chance control trial with unknown allocation;
- Currently under treatment;
- Medical/surgical intervention on the tumour between 123I-MIBG and 68Ga-DOTATATE PET/CT scan.
- Medically unstable or unable to undergo scan.
- Pregnancy (breastfeeding is not an exclusion criterion but needs to be stopped for at least 12 hours after 68Ga-DOTATATE injection).
See the full eligibility criteria
- Newly suspected or biopsy-proven neuroblastoma or recurrence of neuroblastoma
- Planned 123I-MIBG imaging
- Able and willing to provide signed informed consent in French or English (for the adult candidates or the parent/legal tutor of the pediatric candidates)
- Aged between 1 day and 21 years old (inclusively).
- History of another cancer in the past 5 years other than non-melanomatous skin cancer.
- Currently under a assigned by chance control trial with unknown allocation;
- Currently under treatment;
- Medical/surgical intervention on the tumour between 123I-MIBG and 68Ga-DOTATATE PET/CT scan.
- Medically unstable or unable to undergo scan.
- Pregnancy (breastfeeding is not an exclusion criterion but needs to be stopped for at least 12 hours after 68Ga-DOTATATE injection).
- Prior allergic reaction to somatostatin analogues
The study team makes the final eligibility decision.
Where it's taking place
- Montreal, Quebec, Canada
- Sherbrooke, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, up to 21 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Montreal, Quebec, Canada; Sherbrooke, Quebec, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.